Significance of ERβ expression in different molecular subtypes of breast cancer

PurposeThis study is to investigate the estrogen receptor β (ERβ) expression in molecular subtypes of breast cancer and clinic significance of ERβ expression.MethodThe ERβ expression was detected in 730 cases of breast cancer tissue specimens by immunohistochemistry. Twenty-one patients were censored during 2–10 years follow-up. The difference in ERβ expression was analyzed by Pearson Chi-square Test. Its correlation with estrogen receptor α (ERα), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her-2) was analyzed by Spearman rank correlation. The accumulative tumor-free survival rate was calculated by Kaplan-Meier method and difference in survival rate was analyzed by Log-rank test. Cox regression was used for multi-factor analysis.ResultThe ERβ expression was significantly different among the molecular subtypes of breast cancer (P < 0.05). The ERβ expression in breast cancer was positively correlated with Her-2 (P < 0.05) while it had no correlation with ERα and Her-2. The expression of ERα was negatively correlated with Her-2 (P < 0.01) whereas positively correlated with PR (P < 0.01). The expression of PR was negatively correlated with Her-2 (P < 0.05). The tumor-free survival rate in patients with positive ERβ expression was significantly lower than that in patients with negative ERβ expression.ConclusionPositive ERβ expression is a poor prognostic factor of breast cancer.Virtual slidesThe virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1084557586106833

• Publication year

  2014

• Venue

  Diagnostic Pathology

• Publication date

  2014-01-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/1746-1596-9-20PMID 24457087PMCID 3911955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

  2014cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens

  2013cited by this paper
• The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients

  2012cited by this paper
• Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas

  2012cited by this paper
• Immunohistochemical characterization of neoplastic cells of breast origin

  2012cited by this paper
• Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study

  2012cited by this paper
• Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.

  2012cited by this paper
• Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco

  2012cited by this paper
• Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study

  2011cited by this paper
• [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].

  2011cited by this paper
• Current issues in ER and HER2 testing by IHC in breast cancer

  2008cited by this paper
• Expression and significance of estrogen receptor isoforms in different breast tissues

  2007cited by this paper
• Estrogen-receptor biology: continuing progress and therapeutic implications.

  2005cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Oestrogen receptor β in breast cancer: good, bad or still too early to tell?

  2002cited by this paper
• Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers.

  2002cited by this paper
• Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer

  2002cited by this paper
• Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?

  2002cited by this paper
• Role of estrogen receptor beta in estrogen action.

  2001cited by this paper
• HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

  2001cited by this paper
• Estrogen receptors and proliferation markers in primary and recurrent breast cancer

  2001cited by this paper
• Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer.

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Cloning of a novel receptor expressed in rat prostate and ovary.

  1996cited by this paper

• Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression.

  2023cites this paper
• Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer

  2022cites this paper
• Therapeutic potentials of genistein: New insights and perspectives.

  2022cites this paper
• Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator?

  2022cites this paper
• The Prognostic Value of Estrogen Receptor β Isoform With Correlation of Estrogen Receptor α Among Sudanese Breast Cancer Patients

  2021cites this paper
• Splicing regulatory factors in breast cancer hallmarks and disease progression

  2019cites this paper
• Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer

  2019cites this paper
• ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis

  2018cites this paper
• Estrogen receptor β and estrogen receptor α36 predict differential outcome of patients with breast cancer

  2018cites this paper
• Estrogen receptor β inhibits prostate cancer cell proliferation through downregulating TGF-β1/IGF-1 signaling.

  2017cites this paper
• Epithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: A Review and in Silico Investigation

  2016cites this paper
• Targeting Androgen/Estrogen Receptors Crosstalk in Cancer.

  2016cites this paper
• Lactoferrin expression in breast cancer in relation to biologic properties of tumors and clinical features of disease.

  2016cites this paper
• How far have we come in terms of estrogens in breast cancer? [Review].

  2016cites this paper
• The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer

  2016cites this paper
• Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells.

  2015cites this paper
• Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10

  2014cites this paper
• ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

  2014cites this paper
• Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations

  2014cites this paper